Reagents News and Research

RSS

Promega's custom manufacturing capabilities support rapid development of Logix Smart COVID-19 Test

Promega Corporation is being recognized by Utah-based Co-Diagnostics, Inc.

From Promega Corporation 26 Feb 2020

Both strands of microRNA cooperate to drive cancer growth and aggressiveness, research shows

Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer.

20 Feb 2020

A simple, straightforward approach to protein modification

Proteins are essential parts of organisms; thus, they are widely used in medicine, biology and chemistry. Enhancing their inherent properties by adding functional molecules to their structures is a common and important step in many fields.

14 Feb 2020

Hybrid microscope could bring cancer diagnosis into the digital era

By adding infrared capability to the ubiquitous, standard optical microscope, researchers at the University of Illinois at Urbana-Champaign hope to bring cancer diagnosis into the digital era.

12 Feb 2020

MR Solutions installs 3T PET-MR system at Western University’s ImPaKT facility

MR Solutions has installed a 3T PET-MR preclinical imaging system at Western University’s one of a kind ImPaKT Laboratory in Ontario.

From MR Solutions 5 Feb 2020

Coronavirus could spread explosively, tight control needed

The coronavirus may be taking a higher toll of life than we thought, say scientists, in a new study published on January 30, 2020, in The Lancet. But another startling new study based on mathematical modeling, published in the same journal, predicts that almost 76,000 people may have acquired the infection in Wuhan city, and that multiple epidemics in major connected cities inside and outside China may already be brewing. Yet the death rate is markedly low, in this case.

3 Feb 2020

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a pre-clinical animal model of cancer.

From Avacta Life Sciences Ltd. 28 Jan 2020

Scientists visualize diabetes-related proteins at high resolution

Scientists have examined a key receptor for the first time at high resolution - broadening understanding of how it might function, and opening the door to future improvements in treating conditions such as type 2 diabetes.

24 Jan 2020

RNAssist and Rapid Labs agree on a manufacturing and supply agreement for genoPHIX and vivoPHIX

RNAssist has developed several universal biological sample stabilization, fixation and microbial inactivation reagents.

From Rapid Labs Ltd 23 Jan 2020

Synthego adopts good manufacturing practices for highest-quality genome engineering for clinical applications

Synthego, the genome engineering company, today announced it has adopted Good Manufacturing Practice standards to provide academic and industry partners with high-quality reagents for use in clinical research and development.

From Synthego Corporation 23 Jan 2020

Synthego adopts GMP standards for producing sgRNA

Synthego has adopted Good Manufacturing Practice standards for producing customized GMP-grade synthetic guide RNA at its facilities, an initiative the company said will benefit its academic and industry customers as they develop advanced cell and gene therapies.

From Synthego Corporation 23 Jan 2020

High-speed, precise liquid and gas handling products at SLAS 2020

Festo debuts a new generation of high speed, flexible, and precise liquid dispensing and gas handling products at SLAS, January 27-29, in San Diego.

22 Jan 2020

ERS Genomics and New England Biolabs sign agreement to commercialize CRISPR/Cas9 tools, reagents

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs, a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.

From New England Biolabs 9 Jan 2020

Avacta and Daewoong Pharmaceutical announce joint venture to develop novel cell and gene therapies

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, and Daewoong Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company, are pleased to announce that they have agreed to establish a joint venture in South Korea, and to enter a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.

From Avacta Life Sciences Ltd. 9 Jan 2020

New test could help medics to quickly diagnose urinary tract infections

Biological Engineers at the University of Bath have developed a test that could help medics quickly diagnose urinary tract infections, using a normal smartphone camera.

8 Jan 2020

Combined datasets can expedite the discovery and development of new cancer drugs

A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.

20 Dec 2019

Olympus and Ultivue Announce Comarketing Agreement for Leading-Edge Fluorescent Multiplexing Solution

Olympus SLIDEVIEW™ VS200 slide scanner and Ultivue UltiMapper™ reagents meet the changing needs of the scientific community

From Evident Corporation - Life Sciences 18 Dec 2019

Developments in the search for a Zika vaccine - success in mice and a new platform for flavivirus vaccines

Researchers have vaccinated mice against the Zika virus, whilst others have discovered a new platform for flavivirus vaccines.

12 Dec 2019

A recombinant platform for flavivirus vaccines and diagnostics using chimeras

A new technology to produce safer ‘hybrid’ viruses at high volumes for use in vaccines and diagnostics for mosquito-borne diseases has been developed at The University of Queensland.

11 Dec 2019

New technique holds promise in cancer research and science studies

A new technique reported this week in Science overcomes several limitations of typical high-throughput chemical screens conducted on cell samples. Such screens are commonly used to try to discover new cancer drugs, and in many other biomedical applications.

8 Dec 2019